BioLamina, a Stockholm-based biotech scale-up, has secured €20 million in venture debt from the European Investment Bank (EIB). This financing marks a significant milestone for the company, enabling them to scale production of their laminin-based cell culture substrates. The funds will be used to expand development of their technologies, supporting next-generation cell therapies and advanced drug testing methods.
Amount: $20.0M
